S
URGN icon

SignatureFD’s UroGen Pharma URGN Stock Holding History

SignatureFD’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$589 Buy
16
+6
+60% +$163 ﹤0.01% 3337
2026
Q1 		$180 Hold
10
– – ﹤0.01% 3375
2025
Q4 		$234 Hold
10
– – ﹤0.01% 3289
2025
Q3 		$200 Buy
+10
New +$180 ﹤0.01% 3278
2025
Q1 		– Sell
-22
Closed -$234 – 3455
2024
Q4 		$234 Sell
22
-358
-94% -$4.29K ﹤0.01% 3217
2024
Q3 		$4.83K Sell
380
-117
-24% -$1.74K ﹤0.01% 2585
2024
Q2 		$8.34K Sell
497
-153
-24% -$2.18K ﹤0.01% 2350
2024
Q1 		$9.75K Buy
650
+34
+6% +$556 ﹤0.01% 2314
2023
Q4 		$9.24K Buy
616
+536
+670% +$6.96K ﹤0.01% 2293
2023
Q3 		$1.12K Buy
+80
New +$1.28K ﹤0.01% 2915
2021
Q4 		– Sell
-1,509
Closed -$25K – 3277
2021
Q3 		$25K Buy
1,509
+1,322
+707% +$21K ﹤0.01% 1662
2021
Q2 		$3K Buy
187
+59
+46% +$1.07K ﹤0.01% 2497
2021
Q1 		$2K Sell
128
-25
-16% -$531 ﹤0.01% 2541
2020
Q4 		$3K Sell
153
-13
-8% -$272 ﹤0.01% 2187
2020
Q3 		$3K Buy
166
+119
+253% +$2.69K ﹤0.01% 2129
2020
Q2 		$1K Sell
47
-81
-63% -$1.98K ﹤0.01% 2401
2020
Q1 		$2K Sell
128
-2,872
-96% -$77.6K ﹤0.01% 2013
2019
Q4 		$100K Hold
3,000
– – 0.01% 711
2019
Q3 		$71K Buy
+3,000
New +$98.1K 0.01% 795

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SignatureFD's URGN Position: Q2 2026 in Review

SignatureFD increased its UroGen Pharma (URGN) stake by 60% in Q2 2026, buying an estimated $163 and bringing the position to 16 shares worth $589. The position accounts for ﹤0.01% of the portfolio, ranked #3337.

SignatureFD first reported a position in URGN in Q3 2019 and has held it in 19 quarters since. The position peaked at $100K in Q4 2019. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • SignatureFD held 16 shares of UroGen Pharma worth $589 as of Q2 2026.
  • SignatureFD bought 6 UroGen Pharma shares in Q2 2026, an estimated $163.
  • UroGen Pharma made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3337 holding.
  • SignatureFD first reported a position in UroGen Pharma in Q3 2019 and has held it in 19 quarters since.
  • SignatureFD's UroGen Pharma position peaked at $100K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.